|
End-of-day quote
Taipei Exchange
2026-11-20
|
5-day change | 1st Jan Change | ||
| 119.50 TWD | -22.90% |
|
-30.72% | +201.01% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 129B 3.89B 3.54B 3.28B 2.97B 5.57B 363B 5.83B 39.66B 15.73B 196B 14.6B 14.29B 622B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 112B 3.4B 3.1B 2.87B 2.59B 4.86B 317B 5.09B 34.64B 13.74B 171B 12.75B 12.48B 543B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -22.90% | ||
| 1 week | -30.72% | ||
| Current month | -24.84% | ||
| 1 month | -26.01% | ||
| 3 months | +27.26% | ||
| 6 months | +199.87% | ||
| Current year | +201.01% |
| 1 week | 110 | 179 | |
| 1 month | 110 | 187 | |
| Current year | 33.1 | 207 | |
| 1 year | 24.75 | 207 | |
| 3 years | 7 | 207 | |
| 5 years | 7 | 207 | |
| 10 years | 2.7 | 207 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 2016-05-31 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 2022-07-24 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 2016-10-12 |
Cheng Chi Wang
BRD | Director/Board Member | - | 2024-06-26 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 2018-09-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -22.90% | -30.72% | +342.59% | +966.96% | 3.89B | ||
| +0.72% | -5.47% | +30.79% | +128.33% | 1,204B | ||
| +1.77% | -4.94% | +33.77% | +81.21% | 643B | ||
| +1.82% | -2.06% | +25.93% | +108.91% | 501B | ||
| -0.71% | -2.13% | +27.04% | +67.03% | 378B | ||
| +2.46% | -7.49% | +43.94% | +33.13% | 327B | ||
| +0.22% | -4.86% | +27.01% | +51.33% | 285B | ||
| +1.12% | -3.69% | -1.35% | +33.25% | 270B | ||
| +1.34% | -5.10% | +31.50% | +66.55% | 237B | ||
| +1.77% | +0.91% | +35.69% | +123.16% | 207B | ||
| Average | -1.27% | -6.67% | +59.69% | +165.99% | 406B | |
| Weighted average by Cap. | +1.07% | -4.73% | +29.55% | +90.24% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -22.53M -20.53M -19M -17.19M -32.24M -2.1B -33.75M -230M -91.11M -1.14B -84.52M -82.75M -3.6B | -1.36B -41.25M -37.59M -34.79M -31.47M -59.04M -3.85B -61.8M -421M -167M -2.08B -155M -152M -6.6B |
| Net Debt | -5.17B -157M -143M -132M -119M -224M -14.63B -235M -1.6B -633M -7.9B -588M -575M -25.04B | -16.27B -492M -449M -415M -376M -705M -46B -738M -5.02B -1.99B -24.86B -1.85B -1.81B -78.73B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-19 | NT$119.50 | -22.90% | 17,197,420 |
| 26-11-19 | NT$155.00 | -4.62% | 6,781,086 |
| 26-11-18 | NT$162.50 | -2.40% | 2,581,713 |
| 26-11-17 | NT$166.50 | +1.52% | 3,008,437 |
| 26-11-16 | NT$164.00 | -7.87% | 7,557,589 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
















